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Glomerular mRNAs in human type 1 diabetes: Biochemical betic nephropathy in patients with type 1 diabetes [1–3].
evidence for microalbuminuria as a manifestation of diabetic ne- However, more recent data, particularly from renal biop-
phropathy. sies, suggest that microalbuminuria is not truly a “predic-Background. In patients with type 1 diabetes, some consider
tor,” but rather is the earliest clinically identifiable signmicroalbuminuria to be a predictor of diabetic nephropathy while
of diabetic nephropathy [4–6]. Biochemical similaritiesothers believe it is an early feature of diabetic nephropathy.
Methods. Levels of mRNAs that are of pathogenetic rele- in the glomeruli of subjects with microalbuminuria and
vance in diabetic nephropathy were compared in glomeruli those with overt proteinuria support the postulate that
isolated from microalbuminuric and overtly proteinuric sub- microalbuminuria is an early point in the spectrum of dia-jects and in control normoalbuminuric diabetic subjects and
betic nephropathy, rather than a “predictor” of it. Weliving renal transplant donors.
posited that (1) In diabetic nephropathy due to type 1Results. In subjects with microalbuminuria and overt pro-
teinuria, glomerular mRNAs were virtually identical and ap- diabetes, relevant glomerular mRNAs would be increased
proximately twofold higher for connective tissue growth factor compared to those measured in living renal donors (LRD)
(CTGF; P  0.01) and collagen 2(IV) (P  0.03) compared and normoalbuminuric diabetic subjects; and (2) If micro-to living renal donors and normoalbuminuric patients. Glomer-
albuminuria represents an early phase in the spectrum ofular glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
overt diabetic nephropathy, mRNA marker values wouldlevels were not significantly different among the groups (P 
0.4). Weak but statistically significant correlations were noted be similar in glomeruli from microalbuminuric subjects
between CTGF mRNA and albuminuria (assessed by rank), and in those with overt proteinuria.
fractional mesangial surface area, and a composite renal biopsy To test these hypotheses, we performed a cross-sec-index. Glomerular CTGF mRNA correlated inversely with cre-
tional study measuring glomerular type IV collagen andatinine clearance. Glomerular collagen 2(IV) mRNA levels
connective tissue growth factor (CTGF) mRNAs in pa-correlated with albuminuria (by rank) and less strongly with
fractional mesangial area. tients with type 1 diabetes who had either normoalbu-
Conclusion. To our knowledge, these data provide the first minuria, microalbuminuria, or overt proteinuria. Living
biochemical evidence demonstrating that the glomeruli of mi- renal donors (LRD) served as controls.
croalbuminuric patients and those with overt proteinuria do not
differ significantly. The data support the concept that micro-
albuminuria is not “predictive” of diabetic nephropathy, but METHODS
rather is an earlier point in the spectrum of diabetic nephropathy.
Patients
This protocol was approved by the Harbor-UCLA
Ground breaking work in the late 1970s and early 1980s Research and Education Institute Investigational Re-
identified microalbuminuria as a marker of incipient dia- view Board. Renal biopsies were performed for research
and not clinical purposes. Thirty-three renal biopsies
were utilized for mRNA measurements: living renal do-Key words: Type 1 diabetes, diabetic nephropathy, type IV collagen,
connective tissue growth factor, mesangial expansion. nors (N  10); normoalbuminurics (N  12); micro-
albuminurics (N  5); and overt nephropathy (N  6).Received for publication April 18, 2001
In three subjects, material was not available to test alland in revised form July 19, 2001
Accepted for publication July 23, 2001 of the markers. Normoalbuminuria was defined as the
presence of 20 g/min albuminuria on at least two out 2001 by the International Society of Nephrology
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of three timed overnight urine collections and microalbu- serial dilutions of mutated collagen 2(IV) or mimic
CTGF template cDNA were added, and the reactionminuria as 20 to 200 g/min albuminuria. Overt protein-
uria was defined as 500 mg proteinuria on at least one mixture amplified. For collagen 2(IV) mRNA, PCR
proceeded as follows: (1) 94C 3 minutes; (2) 42 cycles24-hour urine collection or 300 mg albuminuria on an
average of three timed overnight collections. of the following sequential steps: 94C  one minute;
60C  one minute, and 72C  3 minutes; and (3)
Clinical data 72C  7 minutes. For CTGF the protocol was modified
as follows: (1) 95C  9 minutes; (2) 36 cycles of theThe following tests were measured in the hospital clini-
cal laboratory: serum creatinine, creatinine clearance, following sequential steps: 95C  30 seconds; 67C 
30 seconds; 95C 30 seconds; and (3) 72C 7 minutes.24-hour urine protein and creatinine, plasma glucose
within three hours prior to biopsy, and hemoglobin A1c For GAPDH, PCR proceeded as per the manufacturer’s
protocol (Clontech, Palo Alto, CA, USA). The RT-PCRlevels (the latter two measures in the diabetics only).
Mean arterial pressure was calculated using measure- products were separated by electrophoresis, the band
densities analyzed by laser densitometry (Helena Labo-ments taken during the outpatient visit prior to the renal
donation or biopsy. Renal size was measured by ultra- ratories, Beaumont, TX, USA), the values log trans-
formed, and a log-linear regression analysis was per-sound in the diabetic patients and by intravenous urogra-
phy or angiography in transplant donors. formed against the mutant or mimic concentration for
each PCR tube. The quantity of cDNA in the test sample
Glomerular microdissection and was defined as that amount at which the mutant or mimic
RT-PCR measurements and wild-type optical density bands were equal.
Microdissection and reverse transcription-polymerase
Primerschain reaction (RT-PCR) measurements were performed
as previously described [7, 8] with minor modifications. The primers for human collagen 2(IV) were TAT
TCC TTC CTC ATG CAC ACG GCG (sense) and CCARenal biopsy was performed in the standard manner and
three to four renal cores obtained. Specimens were im- ATT TTT GGG TTG GCA CC (antisense) [7, 8]. The
primers and competitive mutant for CTGF were ATGmediately aliquoted at the bedside for fixation in alco-
holic Bouin’s solution for light microscopy, snap frozen TCT CCG TAC ATC TTC CTG TAG T (sense) and
GAG TGG GTG TGT GAC GAG CCC AAG G (anti-in isopentane for immunohistochemistry, or placed in glu-
taraldehyde for electron microscopy. One to 1.5 of the sense) [9]. Primers and competitive mutant for human
GAPDH (G3PDH) were purchased from Clontech.cores were placed in vanadyl ribonucleoside complex
(VRC) for preservation of the RNA, and brought to a
Morphological and morphometric assessmentsmicrodissecting microscope for collection within 10 to 20
minutes of the biopsy. For the living renal donors, the Renal biopsies were scored semiquantitatively for the
degree of injury by a pathologist who was unaware ofsame protocol was followed, except that the biopsies
were performed by the transplant surgeon after the kid- the clinical circumstances of the patient from whom the
tissue was obtained. Biopsies were graded on a scale ofney was excised from the donor and before it was placed
in the host. Microdissection was usually completed 0 to 3 in increments of 0.5 for changes in the glomeruli,
tubulointerstitium, and arterioles. The individual scoreswithin 30 minutes. Glomeruli were microdissected at
4C in VRC, rinsed, aliquoted four per tube in RNAse were added to give a final renal biopsy index. The degree
of diabetic glomerulosclerosis (based on diffuse and/orinhibitor, solubilized in triton buffer, lysed by freezing
and thawing, and reverse transcribed (RT) to cDNA nodular increases in mesangial matrix material, amount
of segmental sclerosis, insudates, capillary microaneu-utilizing a Boehringer Mannheim cDNA synthesis kit
(Boehringer Mannheim, Mannheim, Germany). Stan- rysms, and capillary collapse or obliteration) was semi-
quantitated as none, mild, moderate, or severe (scoreddard polymerase chain reaction (PCR) was performed to
check the adequacy of the RT procedure and satisfactory 0 to 3). Arterioles and arteries were assessed as having
no lesions, mild, moderate, or severe involvement basedsamples from all glomeruli from a given patient were
pooled. cDNA from one fifth of a glomerulus per reac- on the amount of hyalinization, muscular wall thick-
ening, and intimal fibrosis. The extent of tubular atrophytion tube was used to measure collagen and CTGF
mRNA, and one tenth of a glomerulus for glyceralde- and interstitial fibrosis were similarly scored. The three
biopsy scores were added yielding a renal biopsy indexhyde-3-phosphate dehydrogenase (GAPDH). Control
samples were simultaneously run in which the RT en- describing pathological changes in each biopsy.
Glomerular surface area was measured using a pointzyme was omitted. Quantitative competitive PCR was
performed using the GeneAmp DNA amplification kit counting method. All non-sclerotic intact glomeruli were
photographed and a grid was superimposed on each pic-(Perkin Elmer Cetus Corp., Norwalk, CT, USA). In each
tube containing test cDNA and amplification reagents, ture. All points falling within the glomerular tufts were
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Table 1. Physiological data in patients with type 1 diabetes
LRD NORMO-DM MICRO-DM OP-DM P
Age years 382 362 353 334 0.6
Range (28–47) (27–48) (25–42) (23–53)
Duration DM years 0 201 162 223 0.16
Range (15–27) (9–23) (14–29)
HbA1c % ND 8.0%0.4 10.3%0.9 9.1%0.8 0.054
Serum creatinine mg/dL 0.80.05 0.90.06 0.90.07 1.70.3 0.001
Creatinine clearance mL/min 1218 1005 1028 7117 0.05
Mean arterial pressure mm Hg 912 872 894 975 0.7
Renal size cm 11.90.7 11.30.3 11.20.3 11.60.5 0.16
Data are expressed as mean SEM. Abbreviations are: LRD, living renal donors; DM, diabetes mellitus; NORMO, normoalbuminuria; MICRO, microalabuminuria;
OP, overt proteinuria; HbA1c, hemoglobin A1c.
counted, including capillary walls and lumina, mesangial compared to the other three groups, but the difference
nevertheless may be clinically significant. Not surpris-regions including overlying basement membranes, and
visceral epithelial cells. Bowman’s space, Bowman’s cap- ingly, serum creatinine was higher and creatinine clear-
ance lower in subjects with overt proteinuria comparedsule and parietal epithelial cells were not included. The
mean number of points in the living donor biopsy glo- to the other three groups. Antihypertensive agents were
not taken, except by one subject with overt nephropathymeruli was taken as the mean control surface area equal
to 1. All glomerular surface areas were then calculated who was on a low dose of an angiotensin-converting
enzyme (ACE) inhibitor.and expressed as a percent relative to the average living
donor biopsy glomeruli as: Albuminuria was measured on timed overnight collec-
tions for the initial group assignment prior to biopsy in
normoalbuminuric and microalbuminuric patients with
Total number of points in the glomerulus  100
Mean number of glomerular points in living
donor glomeruli
diabetes, but was extrapolated to an expected 24-hour
excretion rate to enhance comparability among groups.
(Eq. 1) In living renal donors, the measurement was variably for
albuminuria or proteinuria and the values ranged fromThe fractional mesangial area was measured with a sim-
a minimum of 4.4 mg albumin/day to a maximum ofilar point counting method as previously described [8].
158 mg protein/day. Mean urinary albumin excretion in
Statistics the normoalbuminuric patients was 9.6  2.2 mg albu-
min/day (range 3.8 to 26.6 mg albumin/day). Mean uri-Results were analyzed using Access software, an Excel
nary albumin excretion in the microalbuminuric patientsSpreadsheet (Microsoft, Seattle, WA, USA), and the
was 56.0  17.5 mg albumin/day (range 24.8 to 109.5 mgStatMost software package (DataMost Corp, Salt Lake
albumin/day). Mean proteinuria in the patients withCity, UT, USA). The significance of analysis of variance
overt nephropathy was 4.27  1.49 g/day (range 0.52 to(ANOVA) testing was ascertained using the Student-
9.04 g/day).Neuman-Keul test and Student t test. Fisher’s exact test
Retinopathy was ascertained historically and confirmedwas used to assess non-parametric comparisons among
by physical examination. Of the patients in the normo-groups. The strength of relationships between sets of data
albuminuric group, 2 of 10 had no retinopathy, 6 of 10was tested utilizing either the Pearson correlation coeffi-
had background diabetic retinopathy (BDR), and 2 ofcient or Spearman rank-order correlation test. Results
10 had proliferative retinopathy (PDR). In the micro-are expressed as the mean  standard error of the mean
albuminuric group, 1 of 5 had no retinopathy, 1 of 5(SEM). Significance is assigned at the level of P 	 0.05.
had BDR, and 3 had PDR. In the group with overt
proteinuria, 2 of 6 had mild to moderate BDR and 4 of
RESULTS 6 had PDR.
Clinical data
Glomerular RT-PCR measurementsClinical parameters are summarized in Table 1. There
was no significant difference in the age of the patients Glomerular collagen 2(IV) mRNA levels were low
in living renal donors (1.97 0.52 attm/glomerulus), sim-at biopsy, the duration of diabetes among the groups,
the glycosylated hemoglobin level, or the plasma glucose ilar in normoalbuminurics (1.5  0.28 attm/glomerulus),
and higher in microalbuminurics (3.98  1.49 attm/measured within three hours before the biopsy in the
diabetic subjects. Mean arterial pressure also was not glomerulus) and overtly proteinuric subjects (4.56 
1.56 attm/glomerulus; P 0.03). The patterns for glomer-significantly higher in the subjects with overt proteinuria
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Fig. 1. Glomerular collagen2(IV) and connective tissue growth factor
(CTGF) mRNA levels are nearly identical in microalbuminuric (MA;
) and overtly proteinuric subjects ( ) and higher than in living renal
donors (LRD;) and normoalbuminuric subjects (NA; ). Glomerular
GAPDH mRNA levels were not significantly different. *P  0.03 and
**P  0.01 vs. LRD and NA.
ular CTGF mRNA levels were similar: lowest in living
renal donors (0.06  0.01 attm/glomerulus), similar in
normoalbuminurics (0.07  0.02 attm/glomerulus), and
higher in microalbuminurics (0.14  0.02 attm/glomeru-
lus) and overtly proteinuric subjects (0.13  0.02 attm/
Fig. 2. Diabetic patients in each group showing the range from leastglomerulus; P 0.01). Glomerular GAPDH mRNA lev-
(A, C, E) to most (B, D, F ) diabetic involvement, including mesangialels were not significantly different among the groups. matrix expansion and capillary wall thickening, in glomeruli without
Figure 1 shows these results expressed as a percent of the segmental sclerosis. (A, B) Normoalbuminuric. (C, D) Microalbumi-
nuric. (E, F) Overt proteinuria. (A, B, D–F, periodic acid-methenaminemean control (living renal donor) value. The correlation
silver; C, Masson’s trichrome. All 150)
coefficient between the collagen 2(IV) and the CTGF
mRNA levels was 0.38 (P  0.03)
Morphological and morphometric assessments overt proteinuria (121.0  10.3% and 125.5  7.2%,
The degree of mesangial expansion varied consider- respectively; P  0.05; Fig. 4).
ably within the given diagnostic categories of normo-
Correlational relationships between functional oralbuminuria, microalbuminuria, and overt proteinuria
biopsy data and the mRNA valuesand spanned from little or none to marked proteinuria,
resulting in a substantial overlap among the groups Functional correlations. Proteinuria was measured as
(Fig. 2 A–E). Despite the overlap, the morphometric either urinary total protein or as albuminuria. Therefore,
measurement of fractional mesangial area was lowest in for analytical purposes, subjects were ranked according
the living renal donors (19.0  1.8%), and progressively to amount of proteinuria or albuminuria. Four values
higher in normoalbuminurics (27.3  8.5%), micro- were omitted because they could not be ranked due to
albuminurics (31.9 6.5%), and patients with overt pro- incompatibility of the urinary measurements. Glomeru-
teinuria (44.2  1.8%; P  0.001; Fig. 3). Glomerular lar collagen 2(IV) mRNA was weakly but statistically
surface area was expressed as a % of the mean control significantly correlated with the ranking of diabetic pa-
value observed in living renal donors. The values were tients according to amount of albuminuria/proteinuria
similar in living renal donors and normoalbuminuric dia- (r  0.38, P  0.05) and CTGF mRNA correlated more
betics (100  5.8% and 98.3  6.6%, respectively), and strongly (r 0.68, P 0.0001; Fig. 5). Glomerular CTGF
mRNA also correlated negatively and inversely with cre-were higher in microalbuminuric subjects and those with
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Fig. 4. Glomerular surface area expressed as a % of the mean value
measured in living renal donors. Abbreviations are: LRD, living renal
donors (); NA, normoalbuminuric subjects with type 1 diabetes ( );
MA, microalbuminuric subjects with type 1 diabetes (); Overt, subjects
Fig. 3. Fractional mesangial area demonstrates considerable overlap with type 1 diabetes and overt proteinuria ( ). The overall difference
among the groups as classified by albuminuria or proteinuria. Abbrevia- in mean values among groups was P  0.05. There were no significant
tions are: LRD, living renal donors (); NA, normoalbuminuric subjects differences between LRD and NA or between MA and subjects with
with type 1 diabetes ( ); MA, microalbuminuric subjects with type 1 overt proteinuria. Significant differences were observed between LRD
diabetes (); Overt, subjects with type 1 diabetes and overt proteinuria and MA (P  0.02), LRD and subjects with overt proteinuria (P 
( ). The overall difference in mean values among groups was P  0.002), NA and MA (P 0.02), and NA and subjects with overt protein-
0.001. The difference between LRD and NA, MA, and subjects with uria (P  0.002).
overt proteinuria was P 0.013, P 0.00001, and P 10
7, respectively.
The difference between NA and MA was not significant (P  0.18),
but the difference between NA and subjects with overt proteinuria was
significantly different (P  10
6). The difference between MA and
subjects with overt proteinuria was P  0.001. jects are similar in magnitude and are higher than the
measured values in normoalbuminuric type 1 diabetic
subjects and living renal donors. Thus, these data provide
the first biochemical evidence that in type 1 diabetes,
atinine clearance (r  -0.34, P  0.057), but collagen
microalbuminuria, rather than being a predictor of the
2(IV) mRNA did not (data not shown).
subsequent development of overt diabetic nephropathy,Pathology correlates. Glomerular CTGF mRNA, but
is pathogenetically similar to overt nephropathy, andnot collagen 2(IV) mRNA, correlated with the renal
therefore is more appropriately viewed as an earlierbiopsy index (r 0.45, P 0.05), comprised of a compos-
point in the spectrum of actual diabetic nephropathy.ite score representing changes in mesangial matrix, arte-
These studies also showed positive correlations betweenriolar hyalinosis, and tubulointerstitial fibrosis and atro-
glomerular CTGF mRNA levels and albuminuria, frac-phy (data not shown). Neither CTGF nor collagen 2(IV)
tional mesangial area, and a renal biopsy index includingmRNA correlated with the individual scores for mesan-
composite scores for changes in arterioles, glomeruli, andgial matrix expansion, tubulointerstitial fibrosis, arterio-
the tubulointerstitium. CTGF mRNA values correlatedlar hyalinosis, or the % of completely sclerotic glomeruli.
negatively with creatinine clearance. Finally, the data showGlomerular CTGF mRNA also correlated weakly with
similar correlations between collagen 2(IV) mRNA andfractional mesangial area measured by point counting
albuminuria, and a weaker association with fractional(r 0.4, P 0.04; data not shown). Glomerular collagen
mesangial area.2(IV) mRNA did not correlate with measured frac-
tional mesangial area (r  0.23, P  0.23) when all Type IV collagen and CTGF mRNA: Markers for
samples were considered, but reached significant values defining pathogenetic identity and comparisons to
when only the diabetic subjects were considered for anal- other studies
ysis (r  0.44, P  0.05; data not shown).
We chose to study type IV collagen and CTGF mRNA
as markers because there is good evidence that these
DISCUSSION molecules play a significant role in the pathogenesis of
diabetic nephropathy. Type IV collagen accumulation andHistorically, microalbuminuria was proposed as a pre-
mRNA increments have been documented not only indictor of the subsequent development of nephropathy
the glomeruli of rats and mice with experimental diabetesin patients with type 1 diabetes [1–3]. It is now variably
[10–12], but also in the glomeruli of diabetic patientsviewed as a predictor of diabetic nephropathy or as the
[8, 13–19], although in the latter there may be a totalearliest clinically measurable feature of it [4–6]. Our data
increment in mesangial type IV collagen protein at theshow that glomerular CTGF and collagen2(IV) mRNA
levels in microalbuminuric and overtly proteinuric sub- same time that the density of type IV collagen declines
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of evaluation on type 1 diabetes exclusively. It also is
the only one to examine subjects with normoalbuminuria
and microalbuminuria as well as subjects with overt pro-
teinuria and to compare these results to the findings in
normal glomeruli. Thus, we were able to analyze the
findings in relation to the clinical stage of diabetic ne-
phropathy.
Connective tissue growth factor is a cysteine-rich pep-
tide that is secreted by fibroblasts, endothelial cells, and
mesangial cells after stimulation with transforming growth
factor- (TGF-). It mediates at least some of the down-
stream effects of TGF-, including cell proliferation and
collagen synthesis [9, 21]. CTGF is implicated in the
pathogenesis of diabetic nephropathy. Riser et al showed
increased CTGF mRNA and protein in mesangial cells
exposed to high medium glucose concentration or to the
exogenous provision of TGF-, both features character-
istic of the diabetic state [9]. Elevated CTGF mRNA
levels also were demonstrated in the glomeruli of dia-
betic mice with early nephropathy characterized by mild
mesangial expansion [9]. In a recent preliminary report,
Umezono et al also demonstrated increased CTGF as-
sessed immunohistochemically in diabetic subjects with
mild or moderate nephropathy, albeit with diminished
glomerular CTGF with more advanced nephropathy (ab-
stract; Umezono et al, J Am Soc Nephrol 11:123A, 2000).
Thus, the relevance of the findings demonstrating iden-
tity in glomerular CTGF mRNA values in microalbumi-
nuric and overtly proteinuric type 1 diabetic subjects is
underscored by the importance of CTGF as a pathoge-
netic marker for diabetic nephropathy.
Fig. 5. (A) There was a significant correlation (r  0.4) between a
Lack of effect of glomerular hypertrophy on type IVranking of urinary albumin or protein in individual subjects and their
glomerular collagen 2(IV) mRNA levels (P  0.036). (B) There was collagen and CTGF mRNA levels
a significant correlation (r 0.55) between a ranking of urinary albumin
It is theoretically possible that the increments in typeor protein in individual subjects and their glomerular CTGF mRNA
levels (P  0.0036). IV collagen and CTGF mRNA might have reflected only
glomerular hypertrophy, thus confounding data interpre-
tation. We believe that this is not the case for the follow-
ing reasons. Firstly, there was a similar twofold increment
[8, 13]. In three previously published studies, glomerular in both marker mRNAs studied in subjects with micro-
type IV collagen mRNA was increased in diabetic sub- albuminuria and overt nephropathy, despite no signifi-
jects compared to controls [7, 8, 20]. In one, diabetes cant increment in the control marker GAPDH mRNA,
was not restricted to type 1 diabetes, nephropathy was and actually even a numerical decline (albeit not statisti-
not restricted to diabetes alone, and all of the subjects cally significant) in GAPDH mRNA in the subjects with
studied had more than 500 mg/day of proteinuria [8]. In overt nephropathy and the largest glomeruli. Thus, incre-
the second, the glomerular mRNA measurements did ments in mRNA in large glomeruli are not a generalized
not include comparison to a housekeeping gene, but phenomenon, but rather reflect specific changes. Sec-
instead reported a ratio of two different collagen IV ondly, in this study, as we already had reported in sub-
chains [7]. The latter also lacked normal kidney controls jects with both type 1 and type 2 diabetes assessing type
[7]. In a third, type IV collagen mRNA was increased in IV collagen mRNA alone [8], there were poor correla-
all specimens studied with glomerulosclerosis (including tions between the mRNA measurements and glomerular
diabetic nephropathy), irrespective of the underlying his- size. Taken together, the data dissociate these glomerular
topathology, and control tissue was not studied [20]. Thus, mRNA changes from glomerular size, and emphasize
this is the only report examining glomerular type IV colla- the specificity of the increments observed in type IV
collagen and CTGF mRNA levels.gen mRNA levels in diabetic subjects to focus this type
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